regardless of positive clinical data, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing substantial difficulty from pharmacy benefit managers. The companies are https://rishiqbvc066242.blogaritma.com/39850242/the-drug-faces-is-dealing-with-pbm-hurdles-the-look-of-reimbursement-fights